Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Novel Insights in TKI Resistance in BCR :: ABL1 -Positive B-Cell Acute Lymphoblastic Leukemia Beyond Kinase Domain Mutations

Inge Van Outersterp, Caitlin E.J. Reichert, Aurelie Boeree, Cesca Van De Ven, Brian Kruisinga, Hester A. de Groot-Kruseman, Gabriele Escherich, Anita W. Rijneveld, Judith M. Boer, Monique L. den Boer

Blood (2023) 142 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2023-179704

Published: 2023

Journal Articles

Use of Race and Ethnicity in Sickle Cell Disease Research

Aida Kidane, Minke A.E. Rab, Karlijn Meeks, Amade M'charek, Anita W. Rijneveld

Blood (2023) 142 (Supplement 1): 5317.

https://doi.org/10.1182/blood-2023-179743

Published: 2023

Journal Articles

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Marissa J.M. Traets, Sigrid van der Veen, Jennifer Bos, Laura van Pelt, Aida Kidane, Brigitte A. van Oirschot, Wouter W. van Solinge, Saskia Schols, Mandy N. Lauw, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Eduard J. Van Beers, Anita W. Rijneveld, Richard van Wijk, Minke A.E. Rab

Blood (2023) 142 (Supplement 1): 561.

https://doi.org/10.1182/blood-2023-180755

Published: 2023

Journal Articles

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2023) 142 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2023-172829

Published: 2023

Journal Articles

Red Blood Cell Pyruvate Kinase Properties in Sickle Cell Disease - of Mice and Men

Marissa J.M. Traets, Brigitte A. van Oirschot, Titine J.J. Ruiter, Charles Levine, Anita W. Rijneveld, Judith J.M. Jans, Minke A.E. Rab, Yu-Wei Chen, Richard van Wijk

Blood (2023) 142 (Supplement 1): 1115.

https://doi.org/10.1182/blood-2023-173572

Published: 2023

Journal Articles

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Amir Enshaei, Javier Martinez Martínez Elicegui, Esther Anguiano, Jude Gibson, Mirella Ampatzidou, Michael Doubek, Adele K. Fielding, Edoardo La Sala, Elizabeth Middleton, Anita W. Rijneveld, Amin T. Turki, Ajay Vora, Martin Zimmermann, Anthony V. Moorman

Blood (2022) 140 (Supplement 1): 6369–6370.

https://doi.org/10.1182/blood-2022-157680

Published: 2022

Journal Articles

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers

Blood (2022) 140 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2022-155997

Published: 2022

Journal Articles

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Blood (2022) 140 (Supplement 1): 8890–8892.

https://doi.org/10.1182/blood-2022-163055

Published: 2022

Journal Articles

Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Myrthe J. van Dijk, Minke A.E. Rab, Anita W. Rijneveld, Erfan Nur, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2021) 138 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2021-150234

Published: 2021

Journal Articles

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134088

Published: 2020

Journal Articles

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

Xavier Thomas, MD PhD, Anita W Rijneveld, MD PhD, Nicola Fracchiolla, MD, Cyril Šálek, MD, Alexandros Spyridonidis, MD PhD, Sabina Chiaretti, MD PhD, Naufil Alam, PhD, Isabella Pezzani Grueter, PharmD, Abeera Mohammad, MSc, William Kormany, MD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134470

Published: 2020

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease

Sanne M. Meinderts, Joep W. R. Sins, Karin Fijnvandraat, Sietse Q. Nagelkerke, Judy Geissler, Michael W. Tanck, Christine Bruggeman, Bart J. Biemond, Anita W. Rijneveld, Jean-Louis H. Kerkhoffs, Sadaf Pakdaman, Anoosha Habibi, Robin van Bruggen, Taco W. Kuijpers, France Pirenne, Timo K. van den Berg

Blood (2017) 130 (19): 2121–2130.

https://doi.org/10.1182/blood-2017-05-784876

Published: 2017

Includes: Supplemental data

Journal Articles

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Blood (2016) 128 (22): 123.

https://doi.org/10.1182/blood.V128.22.123.123

Published: 2016

Journal Articles

Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR - ABL1 -like Adult Acute Lymphoblastic Leukemia

Mathijs A. Sanders, PhD, Anikó Szabó, MD, Carla Exalto, Remco Hoogenboezem, Annelieke Zeilemaker, Jasper E. Koenders, Peter van Geel, Anita Schelen, H. Berna Beverloo, PhD, Jan J. Cornelissen, MD PhD, Anita W. Rijneveld, MD PhD, Peter J.M. Valk, PhD

Blood (2016) 128 (22): 4067.

https://doi.org/10.1182/blood.V128.22.4067.4067

Published: 2016

Journal Articles

Value-Based Health Care (VBHC) in Sickle Cell Disease: A Dutch Initiative

Fia ten Brink, MD, Anita W. Rijneveld, MD PhD, Marie-José J.A.G. Claessen, MD, Amando J. Heesterman, Thea J. van Zon, Sonja A.M.C. Teuben, Cora J.D. Onna Van - Walraven, Alice M.A. Goncalves Silva, Francis van Veelen, Renée du Mortier, Marieke A.M.S. Joosten, MD PhD, Fred Petrij, MD PhD, Jan A. Hazelzet, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2015) 126 (23): 5572.

https://doi.org/10.1182/blood.V126.23.5572.5572

Published: 2015

Journal Articles

Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage

Aniko Szabo, MD, Mathijs A. Sanders, MSc, Carla Exalto, Jasper E. Koenders, Patricia G. Hoogeveen, Anita M. Schelen, Willemijn van den Ancker, MD MSc, PhD, Arjan A. van de Loosdrecht, MD PhD, Bob Lowenberg, MD PhD, Vincent H.J. van der Velden, PhD, Jan J. Cornelissen, MD PhD, Peter J.M. Valk, PhD, Anita W. Rijneveld, MD PhD

Blood (2014) 124 (21): 1067.

https://doi.org/10.1182/blood.V124.21.1067.1067

Published: 2014

Journal Articles

Alloantibody Formation In Sickle Cell Disease

Joep Sins, MD, MSc, Saurabh Zalpuri, MD, PhD, Marjon Cnossen, MD, PhD, Anita W. Rijneveld, MD, PhD, Jean-Louis Kerkhoffs, MD, PhD, Alfred van Meurs, MD, Yolanda de Rijke, PhD, Marjolein Peters, MD, PhD, Bart J. Biemond, MD, PhD, Anske van der Bom, MD, PhD, Karin Fijnvandraat, MD, PhD

Blood (2013) 122 (21): 2395.

https://doi.org/10.1182/blood.V122.21.2395.2395

Published: 2013

Journal Articles

Low Mortality In Sickle Cell Patient Cohort with Elevated Tricuspid Regurgitant Jet Flow Velocity

Eduard J. Beers van, MD, PhD, Charlotte F.J. Tuijn, R.N., M.S., Erfan Nur, M.D., Anita W. Rijneveld, M.D., PhD, M. R. Mac Gillavry, M.D., PhD, Ashley Duits, PhD, Dees P Brandjes, M.D., PhD, John-John Schnog, MD, PhD, Bart J. Biemond, MD, PhD

Blood (2010) 116 (21): 1641.

https://doi.org/10.1182/blood.V116.21.1641.1641

Published: 2010

Journal Articles

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

Saman Abbas, Sanne Lugthart, François G. Kavelaars, Anita Schelen, Jasper E. Koenders, Annelieke Zeilemaker, Wim J. L. van Putten, Anita W. Rijneveld, Bob Löwenberg, Peter J. M. Valk

Blood (2010) 116 (12): 2122–2126.

https://doi.org/10.1182/blood-2009-11-250878

Published: 2010

Includes: Supplemental data

NARROW

Novel Insights in TKI Resistance in BCR :: ABL1 -Positive B-Cell Acute Lymphoblastic Leukemia Beyond Kinase Domain Mutations

Use of Race and Ethnicity in Sickle Cell Disease Research

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Red Blood Cell Pyruvate Kinase Properties in Sickle Cell Disease - of Mice and Men

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR - ABL1 -like Adult Acute Lymphoblastic Leukemia

Value-Based Health Care (VBHC) in Sickle Cell Disease: A Dutch Initiative

Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage

Alloantibody Formation In Sickle Cell Disease

Low Mortality In Sickle Cell Patient Cohort with Elevated Tricuspid Regurgitant Jet Flow Velocity

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only